Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PRMT6 | Q96LA8 | 7/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 6/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 3/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19672715 | 0.83 | HDAC4 (0.47) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL16771624 | 0.82 | NOS1 (0.49) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL13181716 | 0.82 | BCHE (0.44) | KDM4ECYP3A4MAPTBCHEBACE1 | |
| SCHEMBL22106570 | 0.82 | CYP3A4 (0.47) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL17827396 | 0.82 | SLC2A1 (0.47) | BCHEBACE1CTSDALDH1A1CA2 | |
| SCHEMBL5022783 | 0.82 | ACHE (0.46) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL19523060 | 0.81 | BCHE (0.49) | KDM4ECYP3A4MAPTBCHEBACE1 | |
| SCHEMBL19102148 | 0.81 | CYP3A4 (0.45) | KDM4ECYP3A4MAPTPRMT6NOS1 | |
| SCHEMBL12956598 | 0.81 | BCHE (0.56) | KDM4EBCHEBACE1CTSDALDH1A1 | |
| SCHEMBL1697126 | 0.80 | MAPT (0.64) | KDM4ECYP3A4MAPTPRMT6NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4059932-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2022-09-21 | — | — | EP | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| EP-3354650-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-9676780-B2 | Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-3016951-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160137646-A1 | Novel Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137646-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | KDM4E 3246/4885CYP3A4 1967/4885MAPT 2173/4885 |
| US-20160194330-A1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | KDM4E 4197/4885CYP3A4 1465/4885MAPT 1836/4885 |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | PRKCQ, PRKCZ, PRKAR2B | KDM4E 2509/4885CYP3A4 2440/4885MAPT 3366/4885 |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | KDM4E 3522/4885CYP3A4 2435/4885MAPT 1024/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | KDM4E 720/4885CYP3A4 1231/4885MAPT 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.